These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19864931)

  • 1. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital.
    Bera E; McCausland K; Nonkwelo R; Mgudlwa B; Chacko S; Majeke B
    AIDS; 2010 Jan; 24(2):283-9. PubMed ID: 19864931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy: A Multicohort Analysis.
    Martinez de Tejada B; Gayet-Ageron A; Winterfeld U; Thorne C; Favarato G;
    J Acquir Immune Defic Syndr; 2019 Mar; 80(3):316-324. PubMed ID: 30570524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.
    Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M;
    BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry.
    Vannappagari V; Albano JD; Koram N; Tilson H; Scheuerle AE; Napier MD
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():6-10. PubMed ID: 26687320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.
    Ford N; Mofenson L; Kranzer K; Medu L; Frigati L; Mills EJ; Calmy A
    AIDS; 2010 Jun; 24(10):1461-70. PubMed ID: 20479637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
    Ford N; Calmy A; Mofenson L
    AIDS; 2011 Nov; 25(18):2301-4. PubMed ID: 21918421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana.
    Bussmann H; Wester CW; Wester CN; Lekoko B; Okezie O; Thomas AM; DeGruttola SM; Makhema J; Essex M; Marlink RG
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):269-73. PubMed ID: 17450102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.
    Williams PL; Crain MJ; Yildirim C; Hazra R; Van Dyke RB; Rich K; Read JS; Stuard E; Rathore M; Mendez HA; Watts DH;
    JAMA Pediatr; 2015 Jan; 169(1):48-55. PubMed ID: 25383770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy outcomes following exposure to efavirenz-based antiretroviral therapy in the Republic of Congo.
    Bisio F; Nicco E; Calzi A; Giacobbe DR; Mesini A; Banguissa H; Vividila NE; Mahoungou P; Boumba JD; Mboungou FA; Bruzzone B; Ratto S; Icardi G; Viscoli C; Bruzzi P
    New Microbiol; 2015 Apr; 38(2):185-92. PubMed ID: 25938743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Ouattara E; Moh R; Amani-Bosse C; Messou E; Sissoko M; Anglaret X; Eholié SP; Danel C; Dabis F; ;
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):183-7. PubMed ID: 21084995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
    Ford N; Mofenson L; Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Shaffer N; Renaud F
    AIDS; 2014 Mar; 28 Suppl 2():S123-31. PubMed ID: 24849471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy.
    Schwartz S; Taha TE; Venter WD; Mehta S; Rees H; Black V
    Infect Dis Obstet Gynecol; 2012; 2012():723096. PubMed ID: 22778534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
    Vannappagari V; Thorne C;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):371-378. PubMed ID: 30939532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of birth defects associated with nelfinavir exposure during pregnancy.
    Covington DL; Conner SD; Doi PA; Swinson J; Daniels EM
    Obstet Gynecol; 2004 Jun; 103(6):1181-9. PubMed ID: 15172850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
    Cressey TR; Stek A; Capparelli E; Bowonwatanuwong C; Prommas S; Sirivatanapa P; Yuthavisuthi P; Neungton C; Huo Y; Smith E; Best BM; Mirochnick M;
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):245-52. PubMed ID: 22083071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007.
    Townsend CL; Willey BA; Cortina-Borja M; Peckham CS; Tookey PA
    AIDS; 2009 Feb; 23(4):519-24. PubMed ID: 19165088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Antiretroviral Pregnancy Registry: Three decades of prospective monitoring for birth defects.
    Albano JD; Scheuerle AE; Watts DH; Beckerman KP; Mofenson LM; Pikis A; Vannappagari V; Seekins D; Cook TS; Tilson H;
    Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5801. PubMed ID: 38798093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11).
    Sibiude J; Mandelbrot L; Blanche S; Le Chenadec J; Boullag-Bonnet N; Faye A; Dollfus C; Tubiana R; Bonnet D; Lelong N; Khoshnood B; Warszawski J
    PLoS Med; 2014 Apr; 11(4):e1001635. PubMed ID: 24781315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry.
    White A; Eldridge R; Andrews E
    Acta Paediatr Suppl; 1997 Jun; 421():86-8. PubMed ID: 9240865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.